Publicacions en col·laboració amb investigadors/es de Universitat de València (8)

2023

  1. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

2018

  1. Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer

    Oncotarget, Vol. 9, Núm. 4, pp. 4395-4410

2016

  1. Analysis of the immune microenvironment in resected non-small cell lung cancer: The prognostic value of different T lymphocyte markers

    Oncotarget, Vol. 7, Núm. 33, pp. 52849-52861

2014

  1. Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma

    European Journal of Cancer, Vol. 50, Núm. 3, pp. 496-505

  2. Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists

    Clinical and Translational Oncology, Vol. 16, Núm. 10, pp. 914-920

2013

  1. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement

    Cancer Discovery, Vol. 3, Núm. 4, pp. 406-417

2011

  1. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor,,in patients with advanced solid tumors

    Journal of Clinical Oncology, Vol. 29, Núm. 28, pp. 3783-3790

2002

  1. Pemetrexed in bladder, head and neck, and cervical cancers

    Seminars in Oncology, Vol. 29, Núm. 6 SUPPL. 18, pp. 69-75